CDX 2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer

From the Herbert Irving Comprehensive Cancer Center, the Department of Pathology and Cell Biology, and the Department of Medicine, Division of Digestive and Liver Diseases, Columbia University, New York (P.D.); Institute for Stem Cell Biology and Regenerative Medicine (P.D., D.S., P.S.R., S.P.M., S.H., J.H., D.Q., M.F.C.) and the Departments of Pathology (X.G., E.F., M.R.), and Medicine, Division of Oncology (N.W.-F., G.A.F., M.F.C.), Stanford University, Stanford, and the Departments of Pediatrics and Computer Science and Engineering, University of California San Diego, San Diego (D.S.) — both in California; Faculty of Engineering, Bar-Ilan University, Ramat Gan, Israel (T.K.); the National Surgical Adjuvant Breast and Bowel Project, NRG Oncology (S.P., G.Y., N.S., N.W.) and the Allegheny Cancer Center at Allegheny General Hospital (N.W.) — both in Pittsburgh; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea (S.P.); and the Department of Biochemistry and Molecular Biology, Medical School of Henan University, Kaifeng, China (X.G.). Address reprint requests to Dr. Dalerba at the Herbert Irving Comprehensive Cancer Center, Columbia University, Irving Cancer Research Center, 1130 St. Nicholas Ave., Rm. 505A, New York, NY 10032, or at pdd2109@ columbia . edu; or to Dr. Clarke at the Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Lorry I. Lokey Stem Cell Research Bldg., 265 Campus Dr., Rm. G2021A, Mail Code 5461, Stanford, CA 94305, or at mfclarke@ stanford . edu.